NIR Process Monitoring Calibration Model Patents: Top Companies & Trends 2026
- 19.8% of all 514 records sit with the top five assignees combined — a leader well ahead of the field but no single-firm lock on the space.
- Filings fell 32% from 2021 to 2024 (25 to 17), the last span the dataset treats as complete, after peaking at 45 filings in 2023.
- G01J and A61B ride alongside core G01N filings at 18.7% and 16.7% of records respectively, showing optical hardware and clinical/diagnostic use are the dominant adjacent claim zones.
Filing growth compares 2021 (25 records) with 2024 (17) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 514 records in scope (CR5), not by the ranked leaders only.
What this patent set covers
This landscape covers patent filings at the intersection of near-infrared (NIR) spectroscopy hardware and the calibration-model workflows that turn raw spectra into usable process measurements: reference sampling, calibration transfer between instruments, prediction-error control, validation-set design and model updating. The scope is bounded by G01N21/359, C12Q3/00 and G01N21/31, which keeps the set anchored to material analysis and testing rather than to spectroscopy hardware in general or to unrelated optical sensing.
The 514 records in scope run from 2015 through mid-2026, with filing activity concentrated in the receiving offices of the United States, Europe and the WIPO PCT route, and a secondary tier in Canada, Australia and Germany. Publication lags filing by roughly 18 months, so 2025 and 2026 figures are still filling in and should be read as a floor, not a ceiling.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 514-record set: how filing volume has moved year over year, and which IPC subclasses carry the claims once G01N material analysis is assumed as the baseline.
Filing trend, 2017-2026
Annual filings rose from 19 in 2017 to a peak of 45 in 2023, then declined to 17 by 2024 — a 32% drop over the 2021-2024 span the dataset treats as complete. Counts for 2025 and 2026 are still incomplete because of publication lag and should not be read as a slowdown.
Technology composition by IPC subclass
Every record in scope carries a G01N classification by construction. Beyond that baseline, G01J (radiation and light measurement) and A61B (diagnosis and surgery) are the two largest adjacent classes, at 18.7% and 16.7% of the 514 records, followed by smaller but distinct clusters in digital data processing, enzyme/DNA measurement, AI-based computing, particle board sensing and computational chemistry — each in the 4.9%-7.4% range. Because records can carry multiple classes, these shares sum to more than 100%.
Shares are the percentage of the 514 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on NIR Process Monitoring Calibration Model with Eureka
This page is one run against one query. Ask Eureka your own question about nir process monitoring calibration model and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
AU2002318275B2 — On-site analysis system with central processor and method of analysing
The filing describes a modular, message-based communication architecture for integrating multiple electronic devices with reduced customisation overhead. Application-specific software components are assembled onto a generic message-based framework, with queuing strategies and business rules accommodated within that framework and intelligent pre-validation applied to messages before they are acted on.Abstract condensed from the original filing for readability.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6280381B1 | Intelligent system for noninvasive blood analyte prediction | 955 |
| 2 | US5750994A | Positive correlation filter systems and methods of use thereof | 667 |
| 3 | US6788965B2 | Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and… | 626 |
| 4 | US6990364B2 | Noninvasive measurement of glucose through the optical properties of tissue | 615 |
| 5 | US6675030B2 | Near infrared blood glucose monitoring system | 493 |
| 6 | US6512937B2 | Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction | 345 |
| 7 | US6646264B1 | Methods and devices for analyzing agricultural products | 291 |
| 8 | US5717209A | System for remote transmission of spectral information through communication optical fibers for real-time on-… | 185 |
| 9 | US20010021803A1 | Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction | 180 |
| 10 | US9554738B1 | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using coll… | 178 |
Citation counts are drawn from within this searched corpus and favour older filings that have had more time to accumulate citations — treat them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three findings that shape where a new filing is likely to land relative to existing claims, and how to read the citation and concentration data without over-reading it.
A visible leader, not a lock-out
The leading assignee holds 26 records and the top five combined account for 19.8% of the 514 records in scope. That is enough to signal a dominant player worth tracking closely, but it leaves roughly four-fifths of the field held by others — this is not a space where one company's claims foreclose entry.
Volume has cooled from its 2023 peak
Filings peaked at 45 in 2023 and the 2021-2024 window shows a 32% decline from 25 to 17. Because publication lag means 2025-2026 figures are still incomplete, this should be read as the field settling after a filing wave, not as an active retreat happening now.
Optical hardware and clinical use are the real adjacent battlegrounds
Beyond the G01N baseline that defines the search, the largest secondary clusters sit in radiation/light measurement hardware (G01J) and diagnostic/surgical application (A61B), meaning calibration-model claims are frequently bundled with instrument design or clinical-use claims rather than filed as pure algorithm patents.
Influence is concentrated in early noninvasive-analyte filings
The most-cited records in this set are early noninvasive blood-analyte prediction patents, which have had the most time to accumulate citations. That makes them useful markers of foundational claim territory in optical analyte prediction, but a poor guide to which techniques are commercially active today.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to nir process monitoring calibration model, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranking covers 100 assignees by record count within this scope. A single leader separates from a long tail, and recent-year filing activity for several previously active names has dropped to zero, which is worth checking before assuming continued momentum.
One clear leader, well ahead of fifth place
The top-ranked assignee holds 26 records against 17 for the fifth-placed assignee, a meaningful gap that marks out a genuine leader rather than a tie among several similarly sized filers.
A fast drop-off after the top ten
Filing counts fall from 17 at fifth place to 9 at tenth, and the top ten combined make up 31.7% of the 514 records in scope — meaning the remaining 90 ranked assignees, plus unranked filers, divide up more than two-thirds of the field.
Recent-year activity has gone quiet for multiple former filers
Several assignees that appear in the ranking, including one with a -100% year-on-year change, show zero filings in the latest year captured. That does not necessarily mean exit from the field given publication lag, but it is a prompt to check whether activity has shifted to a different filing entity or jurisdiction.
| Assignee | Recent year | YoY |
|---|---|---|
| Viavi Solutions Inc. | 0 | — |
| Sensys Medical, Inc. | 0 | — |
| Casco Products Corp. | 0 | — |
| Zyomed Holdings, Inc. | 0 | — |
| Flooring Tech Ltd. | 0 | -100% |
| INNOVATIVE SCI TOOLS | 0 | — |
| Instrumentation Metrics, Inc. | 0 | — |
| W.R. Grace & Co.-Conn. | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, competitive tracking or identifying open claim territory.
Map claims against the leading assignee's portfolio
With 26 records held by the top filer, a claim-by-claim comparison against that portfolio is the fastest way to spot where a new filing would sit too close for comfort.
Explore in EurekaCheck the under-claimed branches before drafting
Calibration transfer, model-update triggers and narrow concentration-range validation show thinner filing density than the core G01N claim space — worth testing before committing a filing strategy.
Run a white space search in EurekaVerify recent-year momentum per assignee
Several tracked assignees show zero filings in the latest year; confirming whether that reflects genuine exit or a shift to a different entity changes how a competitive watch list should be built.
Track assignees in EurekaCommon questions about this landscape
The ranking covers 100 assignees measured by record count within this scope, with a single leader holding 26 records — well ahead of the fifth-placed assignee at 17. The top five assignees combined account for 19.8% of the 514 records in scope, and the top ten account for 31.7%, so while there is a visible leader, the majority of filings are spread across a long tail of smaller filers rather than concentrated in a handful of firms. Anyone doing freedom-to-operate work should still check the full ranked list rather than assume one company covers the space.
Filings rose from 19 in 2017 to a peak of 45 in 2023, then fell to 17 by 2024, a 32% decline over that three-year span. Because patent publication typically lags filing by around 18 months, the 2025 and 2026 counts in this dataset are still incomplete and should not be read as evidence of an ongoing slowdown. The safest reading is that the field passed through a filing wave that peaked in 2023 and has since settled to a lower but still active rate.
Beyond the G01N material-analysis baseline that defines this search, the largest overlapping IPC classes are G01J (radiation and light measurement), covering 18.7% of the 514 records, and A61B (diagnosis and surgery), covering 16.7%. Smaller but distinct clusters appear in digital data processing, enzyme/DNA-based measurement, AI-based computing, particle/fibre-board sensing and computational chemistry, each between roughly 4.9% and 7.4% of records. Because a single record can carry several IPC codes, these figures add up to more than 100% and should not be treated as mutually exclusive categories.
AU2002318275B2 describes a modular, message-based communication architecture for integrating electronic devices with reduced customisation overhead, including queuing strategies, business rules and pre-validation of messages within that framework. It is a systems-integration and communications patent rather than a spectroscopy or chemometric-modelling patent, so it constrains system-architecture choices for on-site analysis platforms more than it constrains the calibration-model mathematics itself. Anyone building an on-site NIR analysis system with a similar modular messaging layer should review its claims specifically, rather than assume it covers calibration methodology broadly.
Filing density is comparatively thin in calibration transfer across instrument batches, model-update triggers for drift correction, and validation-set design for narrow concentration ranges, relative to the volume of filings in the core G01N calibration-model space. AI-assisted prediction-error estimation (G06N, 5.3% of records) and computational-chemistry-assisted spectral modelling (G16C, 4.9%) are also smaller clusters than the optical-hardware and clinical-diagnostic branches. These are reasonable areas to probe further before drafting, though thin filing density signals opportunity rather than guaranteed patentability, so a proper novelty search is still required.
Research NIR Process Monitoring Calibration Model in depth with Eureka
Go past this page: query the whole nir process monitoring calibration model corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.